Kindred Biosciences, Inc.KINNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-11.36%
↓ 153% below average
Average (34q)
21.24%
Historical baseline
Range
High:221.70%
Low:-33.41%
Volatility
1201.3%
High variability
| Period | Value |
|---|---|
| Q2 2021 | -11.36% |
| Q1 2021 | -17.59% |
| Q4 2020 | 3.28% |
| Q3 2020 | -0.15% |
| Q2 2020 | -16.57% |
| Q1 2020 | 24.29% |
| Q4 2019 | -2.14% |
| Q3 2019 | 8.26% |
| Q2 2019 | -5.84% |
| Q1 2019 | -7.79% |
| Q4 2018 | 3.73% |
| Q3 2018 | 28.47% |
| Q2 2018 | 8.87% |
| Q1 2018 | 3.97% |
| Q4 2017 | 5.43% |
| Q3 2017 | 26.15% |
| Q2 2017 | 2.28% |
| Q1 2017 | 7.72% |
| Q4 2016 | -6.53% |
| Q3 2016 | 18.76% |
| Q2 2016 | -8.03% |
| Q1 2016 | -24.94% |
| Q4 2015 | -9.02% |
| Q3 2015 | 0.84% |
| Q2 2015 | 3.78% |
| Q1 2015 | 0.15% |
| Q4 2014 | 27.88% |
| Q3 2014 | -33.41% |
| Q2 2014 | 25.37% |
| Q1 2014 | 46.71% |
| Q4 2013 | 221.70% |
| Q3 2013 | 217.67% |
| Q2 2013 | 112.77% |
| Q1 2013 | 88.57% |
| Q4 2012 | 0.00% |